Bicycle Therapeutics (NASDAQ:BCYC) Earns Equal Weight Rating from Analysts at Stephens

Stephens started coverage on shares of Bicycle Therapeutics (NASDAQ:BCYC) in a research note issued on Friday,Briefing.com Automated Import reports. The firm set an “equal weight” rating and a $25.00 price target on the stock. Stephens’ price objective would indicate a potential upside of 1.21% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on BCYC. Oppenheimer restated an “outperform” rating and issued a $48.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. B. Riley lowered Bicycle Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $33.00 to $28.00 in a report on Wednesday, August 7th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price objective on shares of Bicycle Therapeutics in a report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Bicycle Therapeutics has an average rating of “Moderate Buy” and an average target price of $42.89.

Bicycle Therapeutics Stock Performance

NASDAQ BCYC opened at $24.70 on Friday. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -7.51 and a beta of 0.89. The stock’s 50 day moving average price is $24.32 and its two-hundred day moving average price is $23.14. Bicycle Therapeutics has a 52 week low of $12.54 and a 52 week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. During the same quarter in the prior year, the business posted ($1.26) EPS. The business’s revenue was down 50.0% compared to the same quarter last year. On average, equities research analysts forecast that Bicycle Therapeutics will post -3.08 EPS for the current year.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,212 shares of the company’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the sale, the chief executive officer now directly owns 380,864 shares in the company, valued at $8,478,032.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 4,584 shares of company stock valued at $102,040. 8.50% of the stock is owned by corporate insiders.

Institutional Trading of Bicycle Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Assetmark Inc. bought a new stake in shares of Bicycle Therapeutics during the 3rd quarter worth $34,000. GAMMA Investing LLC raised its position in Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after purchasing an additional 1,038 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Bicycle Therapeutics by 69.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares during the last quarter. XTX Topco Ltd bought a new position in Bicycle Therapeutics in the second quarter valued at about $206,000. Finally, Crossmark Global Holdings Inc. bought a new position in Bicycle Therapeutics in the third quarter valued at about $257,000. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.